' | Peter Y. Kim, M.D. |

Primary Appointment
Degree-Granting Education |
| 2002 | Texas A&M University, College Station, TX, BS, Biomedical Science |
| 2002 | Texas A&M University, College Station, TX, MD, Medicine |
Postgraduate Training |
| 2008-2010 | Cardiology Externship, Cardiology, University Medical and Dental Schools of New Jersey and Cardiovascular Associates of Delaware Valley, Various, NJ |
| 2008-2009 | Hospital Extern, New Jersey Community Hospitals, Various, NJ |
| 2007-2010 | Clinical Fellowship, Cardiovascular, Cooper University Hospital, Camden, NJ |
| 2004-2007 | Clinical Residency, Internal Medicine, UMDNJ-Robert Wood Johnson University Hospital, New Brunswick, NJ |
| 10/2011 | Board of Echocardiography |
| 10/2010 | Cardiovascular Disease |
| 12/2009 | Board of Nuclear Cardiology |
| 8/2007 | American Board of Internal Medicine |
| 2012 | Clinical Safety and Effectiveness Program Graduate (Team Leader)Session 16, The University of Texas MD Anderson Cancer Center |
| 2009-2010 | Chief Cardiology Fellow, Cooper University Hospital |
| 1998-2004 | Medical Science Scholar, Texas A&M University |
| 1998-2002 | President's Endowed Scholarship, Texas A&M University |
| 1998 | National Merit Scholarship Recipient, Texas A&M University |
Letters to the Editor |
| 1. | Yusuf SW, Kim P, Durand JB. Erlotinib or Gefitinib for Non-Small-Cell Lung Cancer. New England Journal of Medicine 364(24):2367, 6/2011. |
© 2010 The University of Texas M. D. Anderson Cancer Center